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Objectives Prostate cancer screening using prostate-specific antigen
(PSA) remains controversial. In deciding about screening, men
must weigh the benefits and harms: little is known about benefit:
harm trade-offs men are willing to accept. The objective of this
study was to assess men’s preferences for PSA screening, and the
trade-offs between benefits and harms men are willing to accept
when deciding about screening.
Methods Preferences of 662 men aged 40–69 were assessed using a
discrete choice experiment. PSA screening was described by six
attributes: prostate cancer deaths, prostate cancer diagnoses,
unnecessary biopsies from false-positive PSA tests, impotence, uri-
nary incontinence/bowel problems and cost. A mixed logit model
was used to examine the influence of attributes on men’s prefer-
ences for PSA testing; benefit: harm trade-offs were also calculated.
Results Men’s preferences were significantly influenced by test
characteristics, particularly potential mortality benefit, unnecessary
biopsies and likelihood of urinary incontinence or bowel problems;
preferences were also influenced by age, prior PSA testing experience
and perceived risk of prostate cancer. Men were willing to accept
between 65 and 233 of 10 000 extra men with unnecessary biopsies,
and between 31 and 72 of 10 000 extra men with incontinence/
bowel problems to avoid one prostate cancer death.
Conclusions Differences in valuations of attributes and trade-offs
acceptable to men of different ages suggest a one size fits all
approach to PSA testing, regardless of age, may not reflect men’s
preferences. Our results can be used by policymakers to ensure
screening programmes are in line with men’s preferences and by clini-
cians and patients to facilitate informed discussions of the most rele-
vant benefits and downsides of PSA screening for an individual man.
doi: 10.1111/hex.12301
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Introduction
Prostate cancer contributes significantly to
both cancer incidence and mortality in men,
leading to almost 240 000 cancer diagnoses
and more than 29 000 deaths per year in the
USA1 and almost 19 000 diagnoses and 3300
deaths per year in Australia.2 However, screen-
ing for prostate cancer using prostate-specific
antigen (PSA) testing remains controversial.
The recent European Randomised Study of
Screening for Prostate Cancer (ERSPC) trial,3
a multicountry PSA screening trial with over
180 000 patients with a median of 11-year fol-
low-up, provides the best evidence of the bene-
fits and harms of PSA screening and suggests
screening offers a small reduction in prostate
cancer-specific mortality,3,4 but substantial
potential harms: screened men have a substan-
tially higher likelihood of prostate cancer diag-
nosis, including diagnosis of cancers that
would not have become clinically apparent
within the man’s lifetime (‘overdiagnosis’).
Consequently, more men therefore experience
attendant harms of diagnosis and treatment
such as consequences of biopsies, and impo-
tence and/or incontinence from treatments.3–6
Because of these potential benefits and
downsides, PSA screening can be considered
preference sensitive health care, that is, health
care where there are significant potential trade-
offs among positive and negative outcomes.
Decisions regarding these interventions should
necessarily reflect an individual’s personal
values and preferences and should be made
after individuals have considered sufficient
information to make an informed choice.7
Indeed, almost all prostate cancer screening
guidelines recommend discussion of the poten-
tial benefits and harms and an individualized,
informed shared decision-making approach to
prostate cancer screening decisions.8–11
Therefore, to make high-quality decisions
about screening, men need to weigh potential
benefits with potential risks, harms and costs.
Decision aids are one means to facilitate
informed decision making by providing a
framework for values clarification;12–14
multicriteria decision analyses are another.15
Some decision tools for PSA screening recog-
nize benefit: harm trade-offs,16 and, as a part
of values clarification, ask men to weigh up
various factors in arriving at a choice. How-
ever, a recent study suggests that information
may be weighted more heavily towards the
pros of screening and therefore may not be
adequate for men to consider and weigh up
benefits and harms.17,18
Few studies to date have explicitly exam-
ined how men trade-off these benefits and
harms in decision making about PSA
screening.19 Where that balance sits for an
individual man is highly personal and driven
by his own personal situation and experi-
ences, such as age and medical history, and
by his preferences about the extent of trade-
offs between benefits and harms that are
acceptable. Preferences of the individual are
therefore paramount and can significantly
influence the use of healthcare services, hence
the increasing emphasis on involvement of
patients in healthcare decisions.20 In making
a decision about prostate cancer screening, a
man, in conjunction with his clinician, may
use a variety of sources of information,
including the preference of other men similar
to him; this is what we seek to provide in
this study.
This study therefore used a discrete choice
experiment (DCE) to investigate how PSA
screening characteristics, and men’s sociodemo-
graphic characteristics, particularly age, influ-
ence preferences for PSA screening and the
trade-offs between benefits and harms that
men are willing to accept in deciding about
screening.
Methods
Study Population and recruitment
This study examines Australian men’s prefer-
ences, using a DCE for prostate cancer screen-
ing using PSA testing,21 and reports the
preferences of 662 men with no family history
of prostate cancer.
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The DCE was conducted as a web-based
survey using an existing general public online
research panel administered by an external
organization (Survey Sampling International,
SSI). From this panel, SSI alerted men aged
40–69 that the survey was available. Men who
had been previously diagnosed or treated for
prostate cancer were excluded, as they are
not eligible for population-based screening. We
used quota sampling to ensure adequate
response numbers in each age group, and
respondents were rewarded with points which
they could redeem for goods, or donate to
charity.
The discrete choice experiments
Men’s preferences were assessed using a
DCE,22–24 a quantitative technique that
assumes a healthcare intervention can be
described by its characteristics (attributes).
Attribute levels are varied systematically in a
series of questions and respondents choose the
option that they prefer for each question.
DCEs can determine which attributes are driv-
ing preferences (e.g. for or against having a
PSA test) and the trade-offs between attributes
that people are willing to accept (e.g. the risk
of complications a man is willing to tolerate in
order to reduce mortality). We followed guide-
lines for the conduct of DCEs.22,23
Attributes and attribute levels
Attributes used to describe prostate cancer
screening were based upon the literature,3,4,25,26
and discussion with clinicians (n = 6); defini-
tions of each attribute were provided to
respondents before they completed the DCE.
PSA screening was described by six attributes:
(i) chance of death from prostate cancer, (ii)
chance of diagnosis of prostate cancer (includ-
ing overdiagnosed cancers in screened men),
(iii) chance of unnecessary biopsies from false-
positive PSA tests, (iv) chance of impotence,
(v) chance of urinary incontinence or bowel
problems and (vi) out of pocket cost (Table 1).
The levels of attributes were based on a model
of PSA test outcomes for men of various ages5
Table 1 DCE attributes and levels for different age groups (chance per 10 000 men, over 10 years)
Attribute 40–49 years 50–59 years 60–69 years
Chance over the next 10 years* Screened Unscreened Screened Unscreened Screened Unscreened
Men who will die from prostate
cancer
1, 3, 5 5 2, 5, 10 10 20, 30, 40 40




5, 10, 15 2 100, 150, 200 50 500, 750,
1000
250
Men who have unnecessary
prostate biopsies from PSA test
false alarms
10, 20, 30 0 300, 400, 500 0 1500, 2000,
2500
0
Men who experience on-going
impotence





Men who experience on-going
urinary incontinence or
moderate to severe bowel
problems
305, 310, 320 300 580, 600, 650 560 750, 800, 850 720
Approximate out of pocket cost








*NB in the choice scenarios, risks were presented as natural frequencies x/10 000; denominators not presented here for brevity.
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and the potential harms associated with treat-
ments of prostate cancer, such as impotence
and urinary or faecal incontinence.26 Test attri-
butes were presented as event chances over
10 years as natural frequencies using a denomi-
nator of 10 000 men who screen, or do not
screen,5 and the cost attribute was presented as
the total direct out of pocket cost they would
personally have to pay over the next 10 years
for any diagnosis and treatment of prostate
cancers that might be detected by screening
(Table 1).
Study design and questionnaire
A two-step pilot study was conducted; 10 men
completed the DCE in a face to face interview,
and a further 106 men aged 40–69 completed
an online pilot questionnaire. We included a
consistency check in the pilot and only two of
the 106 respondents failed this check, suggest-
ing that men were able to understand and com-
plete the 15 discrete choice questions. Men
were asked which attributes they combined
together when answering; as a result, we col-
lapsed urinary and faecal incontinence into one
attribute describing the harms as ‘on-going uri-
nary incontinence or moderate to severe bowel
problems’. There was no difference in the
model when respondents who failed the consis-
tency check were included or excluded; there-
fore, we included them in the analysis. A
mixed logit (ML) model of the pilot data was
estimated, with parameters used to inform the
priors for the final study design.
The final DCE design contained six attributes
with three levels. We created d-efficient frac-
tional factorial designs for each age group
(d-error <0.0006, s-estimates 154–186) using
NGENE design software (www.choice-metrics.
com). Men completed 15 questions, choosing
between three alternatives: two PSA screening
options and one no screening option (Table 2).
One question included a dominated screening
option where the number of prostate cancer
deaths, as well as harms and costs, was higher
than the alternative screening option to assess
men’s understanding of the attribute levels. The
study was approved by the University of
Sydney Human Research Ethics Committee.
Additional sociodemographic information, incl-
uding education, income, employment, marital
status and past experience with PSA testing or
prostate biopsy, perceived risk of prostate can-
cer, and experience of erectile dysfunction was
also collected.
Analysis
We used a ML model with a panel specification.
All demographic variables were effects-coded. A
ML model allows consideration of the full distri-
bution of a parameter estimate and estimates
‘random parameters’. ‘Random parameter’
implies that each individual has an associated
parameter estimate on the specified distribution.
Whilst the exact location of each individual’s
preferences on the distribution may not be
known, estimates of ‘individual-specific prefer-
ences’ can be accommodated by deriving the
individual’s conditional distribution, based –
within sample – on their choices (i.e. prior
knowledge)27 Additional discussion is available
elsewhere.22,24,27 We used a ML model with
2000 Halton draws; random parameters were
specified for the attributes of the DCE, cost
was modelled as a triangular distribution, and
all other benefits and risk parameters were
modelled as normal. The constant and demo-
graphic variables were modelled as non-
random. To understand how men’s prefer-
ences for screening differ by age, age group
was dummy-coded and interactions were cre-
ated between age group and each attribute
describing benefits and risks and estimated
separate attribute coefficients for each age
group; interactions were also created between
dichotomized income level and cost. The con-
stant is interpreted as the underlying prefer-
ence for screening compared to no screening,
regardless of attribute levels. Interactions
between attributes and other respondent char-
acteristics (age, perceived risk, income, educa-
tion, experience of PSA testing or prostate
biopsy, experience of erectile dysfunction)
were also examined before estimating the final
choice model. The optimal utility function,
allowing for segment analysis by age, was:
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V – represents the observable utility for PSA
screening or no screening;
b0 – represents the alternative specific constant
for screening;
b1–15 – represent interaction effects between
screening attributes and respondent age
group;
b16,17 – represent interaction effects and respon
dent income category (<$65 000 vs.
>$65 000 per year);
b18–26 – represent interaction effects between
PSA screening and respondent characteris-
tics (high perceived risk, having a current
partner, having private health insurance,
age, ever having a PSA test, ever having
prostate biopsy, ever having erectile
dysfunction, post-high school education,
income)
For example, the reduced utility function for a
respondent aged 40–49 with an annual income
<$65 000 is shown below:
Models were evaluated for goodness of fit using
the likelihood ratio chi-square statistic for the glo-
bal test of zeromodel coefficients, theMcFadden’s
pseudo R2 and Akaike’s information criterion
(AIC). To achieve the most parsimonious model
possible, without compromising model fit, each
variable that was non-significant was removed
and the model re-estimated. Model fit parameters,
and log likelihood, were assessed after each respe-
cification; non-significant attributes were removed
from utility specifications when their continued
inclusion resulted in a significant change in the log
likelihood. The final model was selected on the
basis of AIC after testing a number of different
model specifications.
Trade-offs between attributes were calculated
as marginal rates of substitution of harms:
benefit (deaths avoided) and are interpreted
as the additional chance of harms that would
be accepted to avoid one extra death from
prostate cancer. We also calculated the willing-
ness to pay for each prostate cancer death
avoided.28,29 We checked the direction of
estimated coefficients to verify whether they
were consistent with a priori expectations and
examined goodness of fit using pseudo R2 and
AIC. All analyses used NLOGIT version 4.01.
(Econometric Software, Castle Hill, NSW,
Australia, www.limdep.com/products/nlogit/).
Vscreening ¼ b0 þ b1deathsAge4049þ b2deathsAge5059þ b3deathsAge6069þ
b4diagnosesAge4049þ b5diagnosesAge5059þ b6diagnosesAge6069þ
b7biopsiesAge4049þ b8biopsiesAge5059þ b9biopsiesAge6069þ b10
impotenceAge4049þ b11impotenceAge5059þ b12impotenceAge6069þ
b13incontinenceAge4049þ b14incontinenceAge5059þ b15incontinenceAge6069þ
b16cost Inc\65Kþ b17cost Inc\65Kþ b18Scr HighRiskþ b19Scr CurrPartner
þ b20Scr HealthInsþ b21Scr Ageþ b22Scr PSAEverþ b23BiopsyEverþ b24Scr EDEver
þ b25Scr Educationþ b26Scr Income
VNoScreening ¼ 0
Where
Vscreening ¼ b0 þ b1deathsþ b4diagnosesþ b7biopsiesþ b10impotenceþ b13incontinence
þ b16costþ b18Scr HighRiskþ b19Scr CurrPartner
þ b20Scr HealthInsþ b21Scr Ageþ b22Scr PSAEverþ b23Scr BiopsyEver
þ b24Scr EDEverþ b25Scr Educationþ b26Scr Income
VNoScreening ¼ 0
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Results
The DCE was completed by 662 men with no
personal history of prostate cancer aged 40–69.
Demographic characteristics are presented in
Table 3. Respondents had a mean age of 55;
70% had a current partner, between 18% and
67% had ever had a PSA test, and between
3% and 10% had ever experienced a prostate
biopsy. Of the 793 men who commenced the
survey, 662 completed it, giving a completion
rate of 83.4%.
Men’s preferences
All 662 respondents were included in the dis-
crete choice analyses. Table 4 shows the results
of the final preference model. Each respondent
completed 15 choices, giving a total of 9930
choice sets. Approximately 35% of men always
chose one of the screening options; 8.5% of men
always chose no screening; 63% of men chose a
screening option in more than 10 of 15 ques-
tions; 15% of men chose screening 6–10 times,
and 21% of men chose screening 5 or fewer
times. Less than 0.5% of men who chose at least
one screening option selected the screening alter-
native where the number of prostate cancer
deaths, as well as harms and costs, was higher
than the alternative screening option, suggesting
men understood the task. The pseudo R2 of 0.37
is approximately equivalent to an R2 of 0.80,
interpreted as explaining approximately 80% of
the variation in the response variable.24
Influence of PSA test characteristics
Avoiding more prostate cancer deaths increased
men’s preference for PSA screening, with the
likelihood of preferring PSA screening varying
with age. Younger men valued mortality bene-
fits more than did older men. (Table 4)
Men were less likely to prefer PSA screening
over no screening as (i) the chance of needing
biopsies increased, (ii) the chance of experienc-
ing incontinence or bowel problems increased
and (iii) out of pocket costs increased (Table 4).
The negative influence of both incontinence/
bowel problems and unnecessary biopsies was
greater in younger men compared to older men.
As cost increased, men were less likely to prefer
screening; the influence of cost did not vary by
age, but did vary slightly by income.
Table 2 Example discrete choice scenario, 50–59 year old men. Please start this text on the line below. These health
outcomes are presented as the chance in 10 000 men who are about the same age as you. These men either participate in
annual PSA screening over the next 10 years (A or B), or do not take part in screening over the next 10 years (C). Choose
the one you would most prefer, after weighing up the pros and cons of the different options
A B C
Chance over the next 10 years
PSA screening
(per 10 000 men)
PSA screening
(per 10 000 men)
No screening
(per 10 000 men)
Men who will die from prostate cancer 2/10 000 5/10 000 10/10 000
Men diagnosed with prostate cancer
(including overdiagnosed cancers in
screened men)
100/10 000 200/10 000 50/10 000
Men who have unnecessary prostate
biopsies from PSA test false alarms
400/10 000 300/10 000 0/10 000
Men who experience on-going impotence 1350/10 000 1375/10 000 1300/10 000
Men who experience on-going urinary
incontinence or moderate to severe
bowel problems
580/10 000 650/10 000 560/10 000
Approximate out of pocket cost to you
over the next 10 years
$2500 $1000 $0
Please pick the option you most prefer ? A B C
□ □ □
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A priori, we expected a higher risk of impo-
tence to make men less likely to prefer PSA
screening to no screening; we also examined
whether men with current or previous experi-
ence of erectile dysfunction (ED) valued the
impotence attribute differently compared to
men who had not experienced ED. The likeli-
hood of impotence did not significantly influ-
ence preferences for screening, and there was
no significant difference between men who cur-
rently or had ever experienced ED compared
to men who had not.
We also expected increases in prostate cancer
diagnoses (including overdiagnosed cancers) to
make men less likely to prefer PSA screening
to no screening. However, the likelihood of
being diagnosed with prostate cancer did not
significantly influence preferences. The non-
significant constant suggests that there was no
underlying preference among respondents for
or against screening in this respondent sample.
Influence of sociodemographic characteristics
Initially, sociodemographic characteristics were
also stratified by age; as there were no signifi-
cant differences in valuations across age
groups, they were collapsed to maintain model
parsimony. Men with high self-perceived risk









n % n % n % n %
Mean age (SD) 55 (9)
Education
Did not complete high school 165 24.9 67 30.5 55 24.9 43 19.5
Completed high school/TAFE/technical/Trade 325 49.1 99 45.0 110 49.8 116 52.5
Completed university 172 26.0 54 24.5 56 25.3 62 28.1
Marital status
Current partner 466 70.4 141 64.1 146 66.1 179 81.0
Divorced/widowed/single 196 29.6 79 35.9 75 33.9 42 19.0
Employment
Full time 292 44.1 142 64.5 109 49.3 41 18.6
Part time/casual 84 12.7 16 7.3 24 10.9 44 19.9
Home/caring duties 17 2.6 8 3.6 7 3.2 2 0.9
Retiree/pensioner 203 30.7 21 9.5 56 25.3 126 57.0
Not working 66 10.0 33 15.0 25 11.3 89 40.3
Annual household income
<$35 000 168 25.4 41 18.6 58 26.2 69 31.2
$35 000–$65 000 168 25.4 54 24.5 44 19.9 70 31.7
$65 001–$95 000 132 19.9 49 22.3 45 20.4 38 17.2
>$95 000 117 17.7 48 21.8 47 21.3 22 10.0
Did not answer 77 11.6 28 12.7 27 12.2 22 10.0
Have private health insurance 323 48.8 100 45.5 96 43.4 127 57.5
Perceived risk of prostate cancer
Lower/much lower than average 191 28.9 63 28.6 48 21.7 80 36.2
About average 422 63.7 143 65.0 155 70.1 124 56.1
Higher/much higher than average 49 7.4 14 6.4 18 8.1 17 7.7
Know anyone outside family with prostate cancer 266 40.2 64 29.1 78 35.3 124 56.1
PSA test, ever 295 44.6 39 17.7 109 49.3 147 66.5
PSA test, previous 12 months 186 28.1 23 10.5 61 27.6 102 46.2
Prostate biopsy, ever 41 6.2 8 3.6 10 4.5 23 10.4
Prostate biopsy, previous 12 months 8 1.2 5 2.3 0 0.0 3 1.4
Erectile dysfunction, ever 217 32.8 41 18.6 68 30.8 108 48.9
Erectile dysfunction, current 151 22.8 23 10.5 42 19.0 86 38.9
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Table 4 Preferences of men for PSA screening compared to no screening
Attribute Coefficient 95% CI
Constant 0.19 –0.06 to 0.44
Deaths (per extra death avoided)
40–49 Mean 0.63* 0.53 to 0.72
SD 0.50* 0.42 to 0.59
50–59 Mean 0.40* 0.34 to 0.46
SD 0.32* 0.28 to 0.36
60–69 Mean 0.08* 0.07 to 0.10
SD 0.04* 0.03 to 0.05
Diagnoses (per extra 100/10 000 men)
40–49 Mean 0.08 –1.16 to 1.00
SD 3.26* 1.93 to 4.59
50–59 Mean 0.02 –0.16 to 0.12
SD 0.05 0.17 to 0.28
60–69 Mean 0.002 –0.03 to 0.03
SD 0.08** 0.04–0.11
Biopsies (per extra 100/10 000 men)
40–49 Mean 0.99** –1.69 to –0.29
SD 0.20 –1.22 to 1.62
50–59 Mean 0.17* 0.25 to 0.08
SD 0.23* 0.13 to 0.33
60–69 Mean 0.06* 0.08 to 0.04
SD 0.06* 0.04 to 0.09
Impotence (per extra 100/10 000 men)
40–49 Mean 0.0009 0.33 to 0.33
SD 0.52* 0.44 to 0.61
50–59 Mean 0.14 0.32 to 0.05
SD 0.02* 0.23 to 0.31
60–69 Mean 0.01 0.05 to 0.03
SD 0.01* 0.02 to 0.05
Incontinence or bowel problems (per extra 100/10 000 men)
40–49 Mean 2.07* 2.88 to 1.25
SD 0.02 0.11 to 0.15
50–59 Mean 0.54* 0.80 to 0.28
SD 0.06 0.007 to 0.12
60–69 Mean 0.17*** 0.33 to 0.01
SD 0.03 0.05 to 0.11
Cost (per extra $100)
Income <$65 000 Mean 0.112* 0.125 to 0.098
SD 0.24* 0.23 to 0.25
Income >$65 000 Mean 0.108* 0.119 to 0.097
SD 0.21* 0.20 to 0.22
Self-perceived risk of prostate cancer (high vs. average/low) Mean 0.40*** 0.004 to 0.79
Marital status (current partner vs. not) Mean 0.07 0.22 to 0.34
Private Health Insurance (vs. not) Mean 0.61* 0.29 to 0.92
Age (per year) Mean 0.15* 0.24 to 0.07
Ever had PSA test (yes) Mean 0.27*** 0.001 to 0.53
Ever had biopsy (yes) Mean 0.58*** 0.02 to 1.12
Ever experienced ED (yes) Mean 0.53*** 0.002 to 1.06
Education (post-high school qualification) Mean 0.10 0.22 to 0.42
Income (higher income category)(>$65 000 per year) Mean 0.08 0.33 to 0.16
*P < 0.001; ** P < 0.01; *** P < 0.05.
McFadden’s R2 (pseudo R2) = 0.37; Akaike’s information criteria = 1.43, Log Likelihood = 6208.86.
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of prostate cancer, who had private health
insurance, had experienced previous PSA tests
or previous prostate biopsy were all more likely
to prefer PSA screening to no screening.
Higher age was associated with a lower
preference for PSA screening compared to no
screening. Neither education nor income level
was significantly associated with screening
preference.
Benefit:harm trade-offs and willingness to pay
Acceptable benefit:harm trade-offs also varied
significantly by age (P < 0.0001, for all paired
comparisons of age groups) (Table 5). To avoid
one prostate cancer death in 10 000 men
screened, men aged 40–49 were willing to accept
an additional 65 of 10 000 men experiencing
unnecessary prostate biopsies and an extra 31 of
10 000 men experiencing incontinence or bowel
problems. Compared to men aged 40–49, older
men were more likely to accept significantly
higher trade-offs, mainly because the harms were
significantly less important for older men com-
pared to younger men. For example, men aged
50–59 were willing to accept an extra 233 of
10 000 men experiencing unnecessary prostate
biopsies and an extra 72 of 10 000 men experi-
encing incontinence or bowel problems to avoid
one prostate cancer death, both of which are
close to estimates reported in the European
Randomised Study of Screening for Prostate
Cancer (ERSPC).3
Younger men also had significantly higher
(P < 0.0001 for all paired comparisons of age
groups) willingness to pay to avoid prostate
cancer deaths (Table 5). Men aged 40–49 were
willing to pay between $717 and $768 over
10 years to avoid one prostate cancer death per
10 000 men screened, whereas men aged 60–69
were willing to pay between $99 and $110 over
10 years. There was no significant difference in
WTP across income levels (greater than or less
than $65 000) with an age group (P > 0.09).
Discussion
Our results indicate men are willing and able
to weigh up potential benefits and harms of
PSA screening in deciding about prostate can-
cer screening. Avoidance of prostate cancer
deaths, the likelihood of prostate biopsy and of
incontinence or bowel problems all significantly
influenced the choice to screen or not; the like-
lihood of prostate cancer diagnosis and of
impotence did not. These results are consistent
with the other stated preference study of PSA
screening.19 Preferences were also influenced by
non-test-related factors such as age, prior PSA
testing experience and perceived risk of pros-
tate cancer. The extent of influence of PSA test
attributes on preferences varied by age, as did
the extent of trade-offs between benefits and
harms that men were willing to accept to avoid
prostate cancer death.
This study uses a DCE to examine the pref-
erences of men for prostate cancer screening
programmes, which, unlike other preference
elicitation methods such as decision aids,
explicitly quantifies the trade-offs between
harms and benefits of PSA testing that men are
willing to accept.20 Depending on their age,
men were willing to accept between 65 and 233
Table 5 Men’s trade-offs: Willingness to accept extra men with harms (per 10 000 screened) to avoid one prostate cancer
death; willingness to pay over 10 years to avoid one prostate cancer death in 10 000 men screened
Extra men with unnecessary
biopsies accepted.
Mean (95% CI), (range)
Extra men with incontinence/
bowel problems accepted.
Mean (95% CI), (range)
WTP (for
income < $65 000)
Mean (95% CI), (range)
WTP(for
income > $65 000)
Mean (95% CI), (range)
40–49 years 65 in 10 000 (59–70) 31 in 10 000 (28–34) $717 ($660–$774) $768 ($709–$826)
Range: 2–158 Range: 1–77 Range: $3–$9790 Range: $2–$8042
50–59 years 233 in 10 000 (224–242) 72 in 10 000 (69–75) $434 ($399–$467) $476 ($440–$510)
Range: 1–751 Range: 1–233 Range: $1–$4576 Range: $1–$4783
60–69 years 153 in 10 000 (149–158) 54 in 10 000 (52–55) $110 ($101–$119) $99 ($91–107)
Range: 39–285 Range: 13–99 Range: $8–$1336 Range: $9–$1066
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extra men with unnecessary prostate biopsies
and between 31 and 72 extra men with inconti-
nence/bowel problems to avoid one prostate
cancer death. The number of extra cases of
incontinence that men were willing to accept to
prevent a cancer death was similar or more
than the number expected per death prevented
based upon the ERSPC trial.3 Similarly, for
men aged 50–59, the number of extra men with
unnecessary biopsies was close to that expected
per death prevented from ERSPC;3 however,
younger and older men were less willing to
accept extra biopsies and, for some, were not
willing to trade as many biopsies as would be
needed from ERSPC to realize a benefit in
terms of a death prevented (around 240 biop-
sies per death prevented).3 Differences in valua-
tions of attributes and extent of trade-offs that
are acceptable to men of different ages suggest
a one size fits all recommendation on PSA test-
ing regardless of age may not reflect men’s
preferences.
Our results were consistent with those of
one previously published stated preference
study of PSA screening19 with respect to the
influence of mortality reduction, risk of unnec-
essary biopsies and costs, as well as some
sociodemographic characteristics on men’s
preferences for screening. Although they also
calculated trade-offs between attributes, they
are not directly comparable to our estimates
of benefit harm trade-offs. de Bekker Grob
et al.19 estimated men’s willingness to accept
worse prostate cancer mortality to avoid
potential screening downsides, such as unnec-
essary biopsies and higher cost; we however
have calculated the willingness of men to
accept more potential downsides to avoid one
prostate cancer death. This means the esti-
mates are not directly comparable, but does
suggest that men are willing and able to make
trade-offs between perceived benefits and
downsides of PSA screening.
A priori, we expected more prostate cancer
diagnoses and impotence would both be associ-
ated with a lower preference for screening.
However, neither attribute had a significant
influence on men’s preferences.
Considering prostate cancer diagnoses first:
there is a common belief that all cancers found
by screening are good because early detection
affords the opportunity for early treatment.30,31
As Gil Welch says ‘. . . the conventional wisdom
is that looking for early cancer always makes
sense. . .’,31 and because of that ‘looking for
cancer has become a cultural norm.’31 How-
ever, by trying to detect disease earlier, we are
also increasing the likelihood of diagnosing
cancers that would never have become clinically
apparent in a man’s lifetime-overdiagnosed
cancers.
However, communicating this concept of
overdiagnosis is not easy. Increasing prostate
cancer diagnoses did not significantly influence
men’s choices; it did not increase the likelihood
of choosing screening, but neither did it mean
that screening was less preferred. There are a
number of possible explanations. The attribute
was described as the total number of prostate
cancer diagnoses, including overdiagnosed can-
cers in screened men, so did not explicitly
describe overdiagnosed cancers. If the attribute
had been presented as overdiagnosed cancers,
rather than total cases of prostate cancer, it
may have been valued differently. It is also
possible that respondents simply did not under-
stand the concept, and implications, of overdi-
agnosis. Overdiagnosed cancers were explained
as follows: ‘PSA screening increases your
chances of being diagnosed with prostate can-
cer compared to not screening. But a reason-
able number of these extra cancers would not
have caused any symptoms. These cancers
probably did not need to be diagnosed and
treated; this is called “overdiagnosis”’ There is
little information in the literature regarding
how consumers understand overdiagnosis, or
about what level of overdiagnosis might be
acceptable for different screening pro-
grammes;32 so it is also possible that this level
of prostate cancer diagnosis was considered an
acceptable trade-off and therefore did not sig-
nificantly influence men’s choices. Further
work is needed to better understand how men
interpret and value overdiagnosis in this
context.
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Impotence also did not significantly influence
men’s choices; this did not differ with men’s
personal experience of erectile dysfunction. It is
unclear whether men did not attach significant
stigma to impotence, and it therefore was not
considered important, or whether impotence is
viewed as a treatable condition given the avail-
ability of pharmacotherapy. It is also possible
that, relative to other potential harms such as
incontinence and on-going bowel problems,
impotence was simply viewed as less important.
This lack of influence of impotence is consis-
tent with other DCE results for treatment
preferences for prostate cancer where the likeli-
hood of impotence did not significantly influ-
ence men’s choice of treatment.33
Study limitations
We acknowledge that our study has a number
of limitations. It assesses men’s stated prefer-
ences for PSA screening compared to no
screening. Although we used rigorous stated
preference design and analysis methods,23,24,27
we cannot rule out that men’s actual screening
behaviour may be different to their stated
choices. In DCEs, it is not feasible to include
every attribute that is important to every
respondent.22 It is necessary to balance the
number of attributes with the complexity of
the task; additional attributes may have been
relevant for some respondents, for example test
frequency was included in de Bekker Grob,19
whereas we included specific attributes for
types of treatment harms by considering impo-
tence and incontinence separately. Attributes
were presented as natural frequencies with a
denominator of 10 000, consistent with risk
presentation literature.5,12 They were presented
explicitly as chances over a 10-year time hori-
zon; it is possible that this time horizon may
have influenced the valuation and the trade-offs
between attributes. It is also possible that some
men may have difficulty in translating the
chance expressed per 10 000 into an estimate
of their individual risk, although a denomina-
tor of 10 000 was specifically chosen because
of the small chance of some events, particularly
in younger men. To enhance face validity and
ensure men saw chances of events that were
appropriate to their age range, we used differ-
ent levels of attributes for each age group;
these differences in level range may have influ-
enced the coefficients estimated. In addition, a
different model specification, for example a
generalized multinomial logit model which
takes account of preference and scale heteroge-
neity, may have resulted in coefficients and
trade-offs. Whilst the online panel is one of the
largest in Australia, with over 1.5 million par-
ticipants ranging from 18–90 + years of age, it
is possible that respondents may not be fully
representative of men in the general commu-
nity. However, characteristics such as educa-
tion level, income and previous PSA test
experience, for which we have population level
data, suggest that respondents were generally
similar to the Australian population, with com-
parable proportions having university level
qualifications34 and PSA test use in the prior
12 months across all age groups.35
Despite these potential limitations, however,
this study uses rigorous design and analysis
methods to quantify men’s preferences for PSA
screening and to explicitly estimate the benefit:
harm trade-offs acceptable to men considering
PSA screening.
Conclusions
For some patients, the decision to screen or
not screen is an easy one; for others, it is
more difficult, and it is these patients who
might benefit from more information about
harms and benefits.36 It is sometimes difficult
to know where the balance might sit for each
of us as individuals, and so patients might
often revert to the ‘what would you do, doc-
tor?’ question as a way of guiding their own
decision making. Rather than relying on the
preferences of physicians for where that bal-
ance lies, our results may help these patients
by telling them how other men of similar age
and risk value the trade-offs between benefits
and harms of PSA testing. Our results can be
used by both clinicians and patients to facili-
tate informed discussions of relevant benefits
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and downsides of PSA screening for an indi-
vidual man. Future research should examine
whether feeding back this information from
DCEs compared to other values clarification
methods helps men in their decision making
in this complex area.
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